Why the study?
Existing therapies for ischemic heart disease and HF are not curative, and clinical evidence remains inadequate to introduce cardioprotective resveratrol into the clinical setting.
Does resveratrol improve outcomes in atherosclerotic cardiovascular disease, myocardial infarction, and heart failure?
Does resveratrol improve outcomes in atherosclerotic cardiovascular disease, myocardial infarction, and heart failure?
Despite promising preclinical data for resveratrol in cardiovascular disease, clinical evidence remains inadequate to support its routine use in practice.
Resveratrol should not enter clinical use for CVD; leaves open whether animal cardioprotection translates to human outcomes.
Atherosclerosis, myocardial infarction (MI) and heart failure (HF) are the main causes of mortality and morbidity around the globe. New therapies are needed to better manage ischemic heart disease and HF as existing strategies are not curative. Resveratrol is a stilbene polyphenolic compound with favorable biological effects that counter chronic diseases. Current evidence suggests that resveratrol is cardioprotective in animal models of atherosclerosis, ischemic heart disease, and HF. Though clinical studies for resveratrol have been promising, evidence remains inadequate to introduce it to the clinical setting. In this narrative review, we have comprehensively discussed the relevant compelling evidence regarding the efficacy of resveratrol as a new therapeutic agent for the management of atherosclerosis, MI and HF.
No takes yet. Share an insight, caveat, or question.
Raj et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: